Navigation Links
Novel Treatment Found To Prolong Survival Of Liver Cancer Patients

Surgery remains the most effective treatment option for patients with liver cancer. A cloud of confusion however remains regarding the best way to treat a patient who harbors a liver tumor that cannot be removed by surgery. //Infact very little surgical options are currently available for this group of patients.

Thanks to the perseverant work of the researchers who have now suggested a novel plan for combating these tumors using radiotherapy. The radiotherapy is targeted precisely at the tumor and is delivered in combination with chemotherapy approximated to a dose of 400 folds the conventional dose. The radiation oncologists designed a treatment that directly targets the tumor, using conformal radiation techniques that pinpoint precisely where the radiation beams go. This unique approach minimizes the radiation exposure to normal liver tissue.

The study was conducted on nearly 128 patients with either cancer of the bile duct, liver or colon that were regarded as inoperable. The study participants received radiation twice daily for two weeks, along with a continuous infusion of the chemotherapy drug floxuridine. The chemotherapy was administered through a catheter into the artery that supplies the liver. A two-week break was allowed before the same regime was continued for another two weeks.

Liver cancers have limited success with radiotherapy owing to the fact that the liver is extremely sensitive to radiation. In addition, multi-drug resistance is a common problem manifested in a majority of the liver cancers. Therefore has not been regarded as a viable option in the treatment strategy.

The study participants had a projected survival rate of eight or nine months. The treatment was found to prolong the survival rate to as much as 15.8 months in a statistically significant way in comparison to the traditional rates. Patients with liver, bile duct and colon cancer were found to live for an average of 15.2, 13.2 and 17.2
'"/>




Page: 1 2

Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Novel Treatment Found Prolong Survival Liver Cancer Patients

(Date:8/22/2014)... Back-to-school time provides an opportunity for parents to develop ... an expert suggests. "Forget New Year,s resolutions; the ... the start of a new fitness and exercise program ... the University of the Sciences in Philadelphia, said in ... likely to build up, "it,s important for mom and ...
(Date:8/22/2014)... attained the distinguished Magnet hospital designation by the ... Considered the gold standard for nursing excellence, the ... professionalism. It is the top international credential for ... Newport Hospital was based on the hospital,s continued ... , "It is a privilege for us to ...
(Date:8/22/2014)... FRIDAY, Aug. 22, 2014 (HealthDay News) -- Many children ... a vaccination, but there are a number of ways ... kids, an expert suggests. The first step is ... the vaccinations help protect their health, said Rita John, ... at Columbia University School of Nursing in New York ...
(Date:8/22/2014)... Women with severe disabilities and multiple chronic conditions ... with no disabilities or no chronic conditions, a new ... often than women with moderate disabilities or women with ... an affiliate scientist with the Li Ka Shing Knowledge ... women with disabilities often have other measures of social ...
(Date:8/22/2014)... Clearwater, FL (PRWEB) August 22, 2014 ... Sauces continues expansion of products in providing new recipe ... for casual wear. , Hailing from Clearwater, Florida, ... would appreciate having 1 card with two to three ... to the recipes on the website. ...
Breaking Medicine News(10 mins):Health News:With Kids in School, Parents Can Work Out 2Health News:Newport Hospital receives nursing's highest credential for third time with Magnet recognition 2Health News:Simple Steps Make Shots Less Scary for Kids, Nurse Says 2Health News:Women with severe, chronic health issues are screened for breast cancer less often 2Health News:Pirate Jonny's Caribbean BBQ Rubs, Seasonings & Sauces Get New Look by Hoisting New Recipe Card Creations and New Clothing Apparel for its Logos 2
... STERIS Corporation (NYSE:, STE ) today announced ... Drug,Administration (FDA) a new liquid chemical sterilization system for ... FDA regarding,issues raised in a May 2008 warning letter ... The new liquid chemical sterilization system,submitted to the FDA ...
... difficulty obtaining credit for capital expenditures, according to Millennium ... Research Group,s (MRG,s) US Markets for Video and ... face increased difficulty obtaining credit at favorable terms to ... US economic crisis. With the economic crisis expected ...
... They are soaked with drugs to target only the ... News) -- A minimally invasive therapy that uses beads ... liver tumors, according to new studies. , ... Microspheres, or beads, combined with cancer-killing chemotherapeutic agents are ...
... manager of Xmark Opportunity Fund, L.P. and Xmark Opportunity Fund, Ltd., sent the first letter below, dated November 29, 2008, ... letter below, dated January 9, 2009, was sent to the Board. ... ... , ...
... Society for Technology in Anesthesia Annual Meeting Quantifies ... Improved ICU UtilizationIRVINE, Calif., Jan. 20 Masimo ... Pulse CO-Oximetry and Measure-Through Motion and Low Perfusion ... clinicians at Dartmouth-Hitchcock Medical Center (DHMC) presented new ...
... Staple Ensures Successful and Productive Call Centers are Created with Used ... ... 2009 -- www.thefsi.com --The Furniture Source, provider of new ... Twin Cities-based call centers enhance the success of their business by ...
Cached Medicine News:Health News:STERIS Corporation Submits New Sterilization System To FDA and Announces Developments on SYSTEM 1 Warning Letter 2Health News:STERIS Corporation Submits New Sterilization System To FDA and Announces Developments on SYSTEM 1 Warning Letter 3Health News:STERIS Corporation Submits New Sterilization System To FDA and Announces Developments on SYSTEM 1 Warning Letter 4Health News:STERIS Corporation Submits New Sterilization System To FDA and Announces Developments on SYSTEM 1 Warning Letter 5Health News:Spending on Integrated Operating Rooms to Slow in 2009, But Expected to Recover in 2010 2Health News:Tiny Chemo Beads Boost Liver Cancer Outcomes 2Health News:Tiny Chemo Beads Boost Liver Cancer Outcomes 3Health News:Xmark Sends Letters to Icagen's Board of Directors: Questions Company's Leadership as Well as Motives Behind Adoption of Poison Pill 2Health News:Xmark Sends Letters to Icagen's Board of Directors: Questions Company's Leadership as Well as Motives Behind Adoption of Poison Pill 3Health News:Xmark Sends Letters to Icagen's Board of Directors: Questions Company's Leadership as Well as Motives Behind Adoption of Poison Pill 4Health News:Xmark Sends Letters to Icagen's Board of Directors: Questions Company's Leadership as Well as Motives Behind Adoption of Poison Pill 5Health News:Xmark Sends Letters to Icagen's Board of Directors: Questions Company's Leadership as Well as Motives Behind Adoption of Poison Pill 6Health News:Xmark Sends Letters to Icagen's Board of Directors: Questions Company's Leadership as Well as Motives Behind Adoption of Poison Pill 7Health News:Xmark Sends Letters to Icagen's Board of Directors: Questions Company's Leadership as Well as Motives Behind Adoption of Poison Pill 8Health News:Xmark Sends Letters to Icagen's Board of Directors: Questions Company's Leadership as Well as Motives Behind Adoption of Poison Pill 9Health News:Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care 2Health News:Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care 3Health News:Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care 4Health News:Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care 5Health News:Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care 6Health News:Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care 7Health News:Used Cubicles from The Furniture Source Help to Eliminate Cubicle Claustrophobia in Call Centers 2
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
(Date:8/21/2014)... 2014  eRelevance Corporation ( www.erelevancecorp.com ), a ... it has completed integration with Nextech, a popular ... and Dermatology practices. "Integration allows our ... practices using Nextech," stated Bob Fabbio , ... from the EMR we are able to automatically ...
(Date:8/21/2014)... BURLINGTON, Mass. , Aug. 21, 2014 /PRNewswire/ ... of COPD,  physicians in Brazil ... to follow clinical guidelines and commonly prescribe long-acting ... regimens, although they do so within current severe ... combinations (FDCs) that are expected to launch in ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3
... of trial triggers $10 million milestone payment to PharmassetPRINCETON, ... VRUS ) and Roche (Roche SWX: RO, ROG; Pink ... been dosed in a Phase IIb study of R7128, ... the treatment of chronic hepatitis C (HCV). The trial ...
... to Initiate in 2010 for BlinatumomabNEW YORK, April 24 ... biopharmaceutical company developing novel, proprietary antibodies for the treatment ... R&D Day for investors and financial analysts at The ... highlighted significant areas of development across Micromet,s BiTE antibody ...
Cached Medicine Technology:Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 2Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 3Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 4